The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition
- 642 Downloads
Here we present the English version of “The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2015 edition.” which was revised in July, 2015. Differences from the most recent previous version include the following newly added clinical questions: CQ19, CQ21, CQ26 and CQ35.
Recommendation grades were changed according to newly reported evidence or on reconsideration of the existing data as follows: CQ4 and CQ8, recommendation for tamoxifen administration for 10 years; CQ5, the recommendation for adjuvant use of exemestane in combination with a luteinizing hormone-releasing hormone (LH-RH) agonist in premenopausal primary breast cancer patients was changed to grade C1; CQ11, the recommendation for adjuvant use of anthracycline and taxane in node-positive primary breast cancer patients was down-graded from A to B; CQ37, the recommendation for multigene signatures as predictive factors for the efficacy of adjuvant chemotherapy...
KeywordsBreast Cancer Tamoxifen Aromatase Inhibitor Adenoid Cystic Carcinoma Invasive Lobular Carcinoma
Conflict of interest
TT received research funding from Takeda, Daiichi-Sankyo and Novartis Pharma. MT received honoraria from AstraZeneca. YY received honoraria from Chugai pharmaceutical and Novartis Pharma, and research funding from Taiho Pharmaceutical. FH received honoraria from Chugai pharmaceutical, and received research funding from Eisai. JT received honoraria from Eisai. YI received manuscript fees paid from Chugai, Eisai and Novartis, and research funding from Novartis, Chugai, Parexel, Eisai, Sanofi, Taiho, EPS, Daiichi-Sankyo and Boehringer Ingelheim. HM received honoraria from Chugai pharmaceutical, AstraZeneca, Eisai, Novartis Pharma, Daiichi-Sankyo, Taiho Pharmaceutical, Boehringer Ingelheim Japan and Ono Pharmaceutical and received research funding from Chugai pharmaceutical, Daiichi-Sankyo, Eisai, Nippon Kayaku, Novartis Pharma, Pfeizer Japan and Sanofi.
- 1.Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized tirals. Lancet. 2011;378(9793):771–84.CrossRefGoogle Scholar
- 2.Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, for the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2012;381(9869):805–16.CrossRefGoogle Scholar
- 5.Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12(7):631–41.CrossRefPubMedGoogle Scholar
- 8.Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M, UK Coordinating Committee on Cancer Research; Ductal Carcinoma in situ Working Party; DCIS trialists in the UK, Australia, and New Zealand. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362(9378):95–102.CrossRefPubMedGoogle Scholar
- 10.Noguchi S, Koyama H, Uchino J, Abe R, Miura S, Sugimachi K, et al. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials. J Clin Oncol. 2005;23(10):2172–84.CrossRefPubMedGoogle Scholar
- 11.Park Y, Okamura K, Mitsuyama S, Saito T, Koh J, Kyono S, et al. Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or III A lymph node-positive breast cancer: a comparative study. Br J Cancer. 2009;101(4):598–604.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, et al. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 trial. J Clin Oncol. 2009;27(9):1368–74.CrossRefPubMedGoogle Scholar
- 13.Ohashi Y, Watanabe T, Sano M, Koyama H, Inaji H, Suzuki T. Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N.SAS-BC 01 trial and CUBC trial). Breast Cancer Res Treat. 2010;119(3):633–41.CrossRefPubMedGoogle Scholar
- 17.Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer:an intergroup trial (E1193). J Clin Oncol. 2003;21(4):588–92.CrossRefPubMedGoogle Scholar
- 21.Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27(33):5529–37.CrossRefPubMedGoogle Scholar
- 25.Anderson SJ, Wapnir I, Dignam JJ, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol. 2009;27:2466–73.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Waeber M, Castiglione-Gertsch M, Dietrich D, et al. Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Ann Oncol. 2003;14:1215–21.CrossRefPubMedGoogle Scholar
- 36.Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008;26(18):3006–14.CrossRefPubMedGoogle Scholar
- 39.Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65.CrossRefPubMedPubMedCentralGoogle Scholar
- 44.Naoi Y, Kishi K, Tsunashima R, Shimazu K, Shimomura A, Maruyama N, et al. Comparison of efficacy of 95-gene and 21-gene classifier (Oncotype DX) for prediction of recurrence in ER-positive and node-negative breast cancer patients. Breast Cancer Res Treat. 2013;140(2):299–306.CrossRefPubMedGoogle Scholar
- 48.Okishiro M, Taguchi T, Jin Kim S, Shimazu K, Tamaki Y, Noguchi S. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer. 2009;115(5):952–61.CrossRefPubMedGoogle Scholar
- 51.Dezentjéé VO, van Schaik RH, Vletter-Bogaartz JM, van der Straaten T, Wessels JA, Kranenbarg EM, et al. CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. Breast Cancer Res Treat. 2013;140(2):363–73.CrossRefGoogle Scholar
- 53.Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst. 2012;104(6):441–51.CrossRefPubMedPubMedCentralGoogle Scholar
- 54.Goetz MP, Sun JX, Suman VJ, Silva GO, Perou CM, Nakamura Y, et al. Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: implications for germline pharmacogenetic studies. J Natl Cancer Inst. 2014;107(2). doi: 10.1093/jnci/dju401.